Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Gamida Cell Ltd. | NiCord (omidubicel) | Severe aplastic anemia | Phase 2 | Trial Discontinued | Intravenous | Hematology |
| Genelux Corporation | Olvimulogene Nanivacirepvec (Olvi-Vec) - (OnPrime/GOG-3076) | Platinum-Resistant or Refractory Ovarian Cancer | Phase 3 | Ongoing | Intraperitoneal | Oncology |
| Genelux Corporation | Olvimulogene Nanivacirepvec (Olvi-Vec) - (VIRO-25) | Malignant pleural effusion (MPE) due to non-small cell lung cancer (NSCLC) or breast cancer | Phase 2 | Ongoing | Intratumoral injection | Oncology |
| GENFIT S.A. | Elafibranor - RESOLVE-IT | Non-alcoholic steatohepatitis (NASH) | Phase 3 | Trial Discontinued | Oral | Gastroenterology |
| GENFIT S.A. | Nitazoxanide | NASH Fibrosis | Phase 2 | Clinical Hold | Oral | Gastroenterology |
| GENFIT S.A. | Elafibranor - RESOLVE-IT | Non-alcoholic steatohepatitis (NASH) | Phase 3 | Trial Discontinued | Oral | Gastroenterology |
| Genmab A/S | Tisotumab vedotin - (innovaTV 207) | Squamous cell carcinoma of the head and neck (SCCHN) | Phase 2 | Data Released | Intravenous | Oncology |
| Genmab A/S | MCLA-129 - (ZENO) | Solid Tumors, MET ex14 NSCLC | Phase 3 | Data Released | Intravenous | Oncology |
